Skip to main content
Retour
Watch Compare

IMPACT BIOMEDICAL INC.

Qualité des données : 100%
IBO
NYSE Manufacturing Chemicals
0,69 €
▼ 0,02 € (-3,10%)
Cap. Boursière: 74,12 M
Prix
0,69 €
Cap. Boursière
74,12 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -1,89 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-36993,75%
Op. Margin-13381,25%

Sécurité

Debt / Equity
N/A
Current Ratio0,04
Interest Coverage-5,40

Valorisation

PE (TTM)
-6,26
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -6,3 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % -36993,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2026 — 20 480,0 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) -20,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 32 000,0 Net Income (TTM) -11,84 M
ROE N/A ROA -63,53%
Gross Margin N/A Operating Margin -13381,25%
Net Margin -36993,75% Free Cash Flow (TTM) -1,89 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,04
Interest Coverage -5,40 Asset Turnover 0,00
Working Capital -22,88 M Tangible Book Value -54,18 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,26 Forward P/E N/A
P/B Ratio N/A P/S Ratio 2316,13
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2,55%
Market Cap 74,12 M Enterprise Value 74,10 M
Per Share
EPS (Diluted TTM) -0,38 Revenue / Share 0,00
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 15,97%
SBC-Adj. FCF -1,90 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 32 000,0 — 50 000,0
Net Income -11,84 M -24,71 M -4,41 M
EPS (Diluted) -0,38 -2,30 -0,07
Gross Profit — — —
Operating Income -4,28 M -28,75 M -4,03 M
EBITDA — — —
R&D Expenses 340 000,0 278 000,0 1,15 M
SG&A Expenses 873 000,0 718 000,0 315 000,0
D&A 1,15 M 1,12 M 1,12 M
Interest Expense 793 000,0 1,07 M 444 000,0
Income Tax -2,58 M 33 000,0 -621 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 17,41 M 20,29 M 44,63 M
Total Liabilities 1,85 M 13,05 M 16,37 M
Shareholders' Equity 12,61 M 4,26 M 25,22 M
Total Debt — — —
Cash & Equivalents 3 000,0 2,00 M 1 000,0
Current Assets 411 000,0 2,45 M 332 000,0
Current Liabilities 1,16 M 9,79 M 13,14 M